Physician profile
Sheetal Sharma
NPI 1538328885
$1,121.68
in general payments reported to CMS, 2019-2025
12 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $81.71 · 2021: $141 · 2022: $55.82 · 2023: $173 · 2024: $136 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $474.54 | 2021-2024 | Spyglass, Exalt Model D |
| Pfizer INC. | $225.54 | 2019-2024 | |
| Abbvie INC. | $170.45 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.69 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.96 | 2019 | |
| Shionogi INC | $31.14 | 2019 | |
| Janssen Biotech, INC. | $29.20 | 2019-2020 | |
| Alfasigma USA, INC. | $22.25 | 2020 | |
| Astellas Pharma US INC | $20.23 | 2025 | Veozah |
| Qol Medical, LLC | $14.05 | 2019 | |
| Medtronic, INC. | $13.60 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.